|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Babjuk M: Trends in bladder cancer
incidence and mortality: Success or disappointment? Eur Urol.
71:109–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nadal R and Bellmunt J: Management of
metastatic bladder cancer. Cancer Treat Rev. 76:10–21. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Loehrer PJ Sr, Einhorn LH, Elson PJ,
Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R,
Sarosdy MF, Lowe BA, et al: A randomized comparison of cisplatin
alone or in combination with methotrexate, vinblastine, and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol. 10:1066–1073. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zou W, Wolchok JD and Chen L: PD-L1
(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms,
response biomarkers, and combinations. Sci Transl Med.
8:328rv3242016. View Article : Google Scholar
|
|
7
|
Aggen DH and Drake CG: Biomarkers for
immunotherapy in bladder cancer: A moving target. J Immunother
Cancer. 5:942017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carosella ED, Ploussard G, LeMaoult J and
Desgrandchamps F: A systematic review of immunotherapy in urologic
cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and
HLA-G. Eur Urol. 68:267–279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xue Y, Tong L, Liu F, Liu A, Liu A, Zeng
S, Xiong Q, Yang Z, He X, Sun Y and Xu C: Tumor infiltrating M2
macrophages driven by specific genomic alterations are associated
with prognosis in bladder cancer. Oncol Rep. 42:581–594.
2019.PubMed/NCBI
|
|
10
|
Miyake M, Tatsumi Y, Gotoh D, Ohnishi S,
Owari T, Iida K, Ohnishi K, Hori S, Morizawa Y, Itami Y, et al:
Regulatory T Cells and tumor-associated macrophages in the tumor
microenvironment in non-muscle invasive bladder cancer treated with
intravesical bacille calmette-guerin: A long-term follow-up study
of a Japanese cohort. Int J Mol Sci. 18:2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang W, Zhu D, Wang C and Zhu Y: An
immune relevant signature for predicting prognoses and
immunotherapeutic responses in patients with muscle-invasive
bladder cancer (MIBC). Cancer Med. 9:2774–2790. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Witten DM and Tibshirani R: A framework
for feature selection in clustering. J Am Stat Assoc. 105:713–726.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
da Silveira WA, Hazard ES, Chung D and
Hardiman G: Molecular profiling of RNA tumors using high-throughput
RNA sequencing: From raw data to systems level analyses. Methods
Mol Biol. 1908:185–204. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bhattacharya S, Andorf S, Gomes L, Dunn P,
Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J,
et al: ImmPort: Disseminating data to the public for the future of
immunology. Immunol Res. 58:234–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wan B, Liu B, Huang Y, Yu G and Lv C:
Prognostic value of immune-related genes in clear cell renal cell
carcinoma. Aging (Albany NY). 11:11474–11489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu G, Wang LG, Han Y and He QY:
ClusterProfiler: An R package for comparing biological themes among
gene clusters. Omics. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heagerty PJ and Zheng Y: Survival model
predictive accuracy and ROC curves. Biometrics. 61:92–105. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fornes O, Castro-Mondragon JA, Khan A,
Khan A, Lee RVD, Zhang X, Richmond PA, Modi BP, Correard S,
Gheorghe M, et al: JASPAR 2020: Update of the open-access database
of transcription factor binding profiles. Nucleic Acids Res.
48:D87–d92. 2020.PubMed/NCBI
|
|
23
|
Song J, Deng Z, Su J, Yuan D, Liu J and
Zhu J: Patterns of immune infiltration in hnc and their clinical
implications: A gene expression-based study. Front Oncol.
9:12852019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M,
et al: EAU Guidelines on non-muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Felsenstein KM and Theodorescu D:
Precision medicine for urothelial bladder cancer: Update on tumour
genomics and immunotherapy. Nat Rev Urol. 15:92–111. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shu B, Zhang J, Sethuraman V, Cui G, Yi X
and Zhong G: Transcriptome analysis of Spodoptera frugiperda Sf9
cells reveals putative apoptosis-related genes and a preliminary
apoptosis mechanism induced by azadirachtin. Sci Rep. 7:132312017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rui X, Shao S, Wang L and Leng J:
Identification of recurrence marker associated with immune
infiltration in prostate cancer with radical resection and build
prognostic nomogram. BMC Cancer. 19:11792019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang S, Zhang E, Long J, Hu Z, Peng J,
Liu L, Tang F, Li L, Ouyang Y and Zeng Z: Immune infiltration in
renal cell carcinoma. Cancer Sci. 110:1564–1572. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rosenberg J and Huang J: CD8(+) T Cells
and NK cells: Parallel and complementary soldiers of immunotherapy.
Curr Opin Chem Eng. 19:9–20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He QF, Xu Y, Li J, Huang ZM, Li XH and
Wang X: CD8+ T-cell exhaustion in cancer: Mechanisms and
new area for cancer immunotherapy. Brief Funct Genomics. 18:99–106.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mitchell S, Vargas J and Hoffmann A:
Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med.
8:227–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Imanishi T and Saito T: T Cell
co-stimulation and functional modulation by innate signals. Trends
Immunol. 41:200–212. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Asprodites N, Zheng L, Geng D,
Velasco-Gonzalez C, Sanchez-Perez L and Davila E: Engagement of
Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and
augments antitumor activity. Faseb J. 22:3628–3637. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chi D, Xu W, Tao X, Zhang T and Cui Y:
PD-L1 expression in colorectal cancer and its relationship with
TLR-4 expression. J Buon. 25:1423–1429. 2020.PubMed/NCBI
|
|
36
|
Dan L, Liu L, Sun Y, Song J, Yin Q, Zhang
G, Qi F, Hu Z, Yang Z, Zhou Z, et al: The phosphatase PAC1 acts as
a T cell suppressor and attenuates host antitumor immunity. Nat
Immunol. 21:287–297. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Elangovan IM, Vaz M, Tamatam CR, Potteti
HR, Reddy NM and Reddy SP: FOSL1 promotes kras-induced lung cancer
through amphiregulin and cell survival gene regulation. Am J Respir
Cell Mol Biol. 58:625–635. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo YZ, He P and Qiu MX: FOSL1 enhances
growth and metastasis of human prostate cancer cells through
epithelial mesenchymal transition pathway. Eur Rev Med Pharmacol
Sci. 22:8609–8615. 2018.PubMed/NCBI
|
|
39
|
Rodriguez-Aguayo C, Bayraktar E, Ivan C,
Aslan B, Mai J, He G, Mangala L, Jiang D, Nagaraja A, Ozpolat B, et
al: PTGER3 induces ovary tumorigenesis and confers resistance to
cisplatin therapy through up-regulation
Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 40:290–304. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Coupland KG, Kim WS, Halliday GM, Hallupp
M, Dobson-Stone C and Kwok JB: Role of the long non-coding RNA
MAPT-AS1 in regulation of microtubule associated protein tau (MAPT)
expression in parkinson's disease. PLoS One. 11:e01579242016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wosnitzer MS, Domingo-Domenech J,
Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC,
McKiernan JM and Cordon-Cardo C: Predictive value of microtubule
associated proteins tau and stathmin in patients with nonmuscle
invasive bladder cancer receiving adjuvant intravesical taxane
therapy. J Urol. 186:2094–2100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Riese DJ 2nd and Cullum RL: Epiregulin:
roles in normal physiology and cancer. Semin Cell Dev Biol.
28:49–56. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cao R, Yuan L, Ma B, Wang G, Qiu W and
Tian Y: An EMT-related gene signature for the prognosis of human
bladder cancer. J Cell Mol Med. 24:605–617. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen Z, Liu G, Hossain A, Danilova IG,
Bolkov MA, Liu G, Tuzankina IA and Tan W: A co-expression network
for differentially expressed genes in bladder cancer and a risk
score model for predicting survival. Hereditas. 156:242019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu S, Suo J, Wang C, Sun X, Wang D, He L,
Zhang Y and Li W: Prognostic significance of low miR-144 expression
in gastric cancer. Cancer Biomark. 20:547–552. 2017. View Article : Google Scholar : PubMed/NCBI
|
